Literature DB >> 25468916

Spatial and temporal cancer evolution: causes and consequences of tumour diversity.

Crispin T Hiley1, Charles Swanton2.   

Abstract

Our knowledge of the morphological heterogeneity of cancer has recently been augmented by the genomic heterogeneity revealed by the use of next-generation sequencing technology. We now know that no two cancers are alike and that even different regions within the same tumour vary in their composition. Tumours consist of multiple clonal populations and they evolve under Darwinian principles. This review summarizes some of the causes of such diversity and its implication for cancer management.
© 2014 Royal College of Physicians.

Entities:  

Keywords:  Cancer; evolution; heterogeneity; resistance

Mesh：

Year:  2014        PMID： 25468916     DOI： 10.7861/clinmedicine.14-6-s33

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   2.659


  12 in total

1.  Computational Tools for Parsimony Phylogenetic Analysis of Omics Data.

Authors:  Jose Salazar; Hakima Amri; David Noursi; Mones Abu-Asab
Journal:  OMICS       Date:  2015-06-03

2.  Mechanisms that determine nanocarrier targeting to healthy versus inflamed lung regions.

Authors:  Jacob S Brenner; Kartik Bhamidipati; Patrick M Glassman; N Ramakrishnan; Depeng Jiang; Andrew J Paris; Jacob W Myerson; Daniel C Pan; Vladimir V Shuvaev; Carlos H Villa; Elizabeth D Hood; Raisa Kiseleva; Colin F Greineder; Ravi Radhakrishnan; Vladimir R Muzykantov
Journal:  Nanomedicine       Date:  2017-01-05       Impact factor: 5.307

Review 3.  Next-Generation Sequencing to Guide Clinical Trials.

Authors:  Lillian L Siu; Barbara A Conley; Scott Boerner; Patricia M LoRusso
Journal:  Clin Cancer Res       Date:  2015-10-15       Impact factor: 12.531

Review 4.  Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas.

Authors:  Harvey Schwartz; Brad Scroggins; Abbey Zuehlke; Toshiki Kijima; Kristin Beebe; Alok Mishra; Len Neckers; Thomas Prince
Journal:  Cell Stress Chaperones       Date:  2015-06-13       Impact factor: 3.667

5.  Genomic landscape of pathogenic mutation of APC, KRAS, TP53, PIK3CA, and MLH1 in Indonesian colorectal cancer.

Authors:  Vania Myralda Giamour Marbun; Linda Erlina; Toar Jean Maurice Lalisang
Journal:  PLoS One       Date:  2022-06-16       Impact factor: 3.752

Review 6.  Challenges of deciphering gastric cancer heterogeneity.

Authors:  Petra Hudler
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

7.  Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients.

Authors:  Elza C de Bruin; Jessica L Whiteley; Claire Corcoran; Pauline M Kirk; Jayne C Fox; Javier Armisen; Justin P O Lindemann; Gaia Schiavon; Helen J Ambrose; Alexander Kohlmann
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

8.  Measurement of separase proteolytic activity in single living cells by a fluorogenic flow cytometry assay.

Authors:  Wiltrud Haaß; Helga Kleiner; Martin C Müller; Wolf-Karsten Hofmann; Alice Fabarius; Wolfgang Seifarth
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

9.  Centromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy.

Authors:  Weiguo Zhang; Jian-Hua Mao; Wei Zhu; Anshu K Jain; Ke Liu; James B Brown; Gary H Karpen
Journal:  Nat Commun       Date:  2016-08-31       Impact factor: 14.919

Review 10.  Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform.

Authors:  C Gilson; S Chowdhury; M K B Parmar; M R Sydes
Journal:  Clin Oncol (R Coll Radiol)       Date:  2017-10-25       Impact factor: 4.126
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.